Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
There are few available options for treating Pulmonary hypertension in COPD and this statement may help a better understanding.
"Long-term supplemental oxygen remains the primary treatment in COPD patients with PH. The administration of new vasodilators (prostanoids, endothelin-1 receptor antagonists and phosphodiesterase-5 inhibitors) dedicated to idiopathic pulmonary arterial hypertension in the disproportionate subgroup of patients with "out-of-proportion" PH may be considered in the setting of clinical trials. The use of these drugs in COPD patients with PH < 40 mmHg may worsen gas exchange, and to date, has no proven benefit.
Further novel agents under review/trials are "5-HT receptor antagonists, Rho-kinase inhibitors, statins and stem cell therapy.
Reference:Curr Drug Targets. 2011 Apr;12(4):501-13. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. Zakynthinos E1, Daniil Z, Papanikolaou J, Makris D.
PharmD Info is an online forum dedicated to the pharmacy professionals. The goal of this website is to create a good communication platform in the web for the pharmacists to enhance their knowledge,skills and Inter-professional relationships through various online discussions.